Preclinical studies demonstrated synergistic or additive effects of PPARγ ligands with chemotherapeutic agents on cancer cell apoptosis and growth inhibition, and suggested their potential clinical use in cancer therapy [4–7]. The gene discussed is PPARG; the disease is cancer.